Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13575
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDrouvalakis, K Aen
dc.contributor.authorBuchanan, Russell R Cen
dc.date.accessioned2015-05-16T03:27:23Z
dc.date.available2015-05-16T03:27:23Z
dc.date.issued1998-02-01en
dc.identifier.citationThe Journal of Rheumatology; 25(2): 290-5en
dc.identifier.govdoc9489821en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13575en
dc.description.abstractTo assess the phospholipid specificity of lupus anticoagulants (LAC) in autoimmune and drug induced LAC positive patients, and to determine their relevance with the clinical feature thrombosis.Thirty-five plasma samples with LAC were tested. Of these, 22 samples were from patients with autoimmune disease: 12 had systemic lupus erythematosus (SLE) and 10 primary antiphospholipid syndrome (APS). These were compared with 13 patients with drug induced LAC. Antiphospholipid (aPL) activity was tested by inhibition of LAC activity in a modified coagulation assay using the phospholipids: egg phosphatidylethanolamine (PE), 20% phosphatidylserine/80% phosphatidylcholine (PS/PC), and 15% PS/65%PC/20%PE mixture. Anticardiolipin antibodies (aCL) were measured in all samples by ELISA.In the autoimmune group, 95% were positive for reactivity to PE, 68% for PS/PC, 68% for PS/PC/PE, and 77% aCL. Of the drug induced group, 69% were positive for reactivity to PE, but only 23% for PS/PC, 46% PS/PC/PE, and 23% aCL positive. In the autoimmune patient group, 64% had thrombotic episodes, all of which had anti-PE activity, and 64% had associated anti-PS activity. No drug induced patient had episodes of thrombosis.Autoimmune induced LAC may contain a broader range of phospholipid specificities than those from drug induced patients. These data thus identify another potential reason why patients with drug induced LAC appear to be at less risk of developing APS than those with autoimmune LAC.en
dc.language.isoenen
dc.subject.otherAntibody Specificityen
dc.subject.otherAntiphospholipid Syndrome.immunologyen
dc.subject.otherBlood Coagulation Testsen
dc.subject.otherDrug-Related Side Effects and Adverse Reactionsen
dc.subject.otherHumansen
dc.subject.otherLupus Coagulation Inhibitor.immunologyen
dc.subject.otherLupus Erythematosus, Systemic.immunologyen
dc.subject.otherPartial Thromboplastin Timeen
dc.subject.otherPhosphatidylcholines.chemistryen
dc.subject.otherPhosphatidylethanolamines.immunologyen
dc.subject.otherPhosphatidylserines.chemistryen
dc.subject.otherPhospholipids.immunologyen
dc.subject.otherThrombosis.immunologyen
dc.titlePhospholipid specificity of autoimmune and drug induced lupus anticoagulants; association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe Journal of rheumatologyen
dc.identifier.affiliationUniversity of Melbourne, Department of Medicine, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australiaen
dc.description.pages290-5en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/9489821en
dc.type.austinJournal Articleen
local.name.researcherBuchanan, Russell R C
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
crisitem.author.deptRheumatology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 2, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.